Eli Lilly and Company (LLY) 2024 10-K Earnings Analysis
Eli Lilly and Company2024 Earnings Analysis
77/100
Eli Lilly's FY2024 10-K captures the GLP-1 revolution in motion: revenue grew to $45.0B and net income reached $10.6B at 23.6% net margin — respectable pharma numbers, though weighed down by heavy capex for Mounjaro/Zepbound manufacturing build-out. Gross margin of 81.3% confirms the premium patent-protected economics. The ROE of 74.2% is engineered by buybacks shrinking equity to $14.3B against $72.3B assets. The 10-K flags standard pharma risks including 'issues with product supply and regulatory approvals stemming from manufacturing difficulties' — directly relevant as Zepbound demand exceeded supply throughout FY2024.
Filing analysis
Eli Lilly and Company 2024 10-K Analysis
This page reads Eli Lilly and Company's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 77/100, or grade C.
LLY Earnings Quality
The earnings-quality module scores 83/100, with Gross Margin: 81.3%, Revenue Growth: +32% YoY. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
LLY Economic Moat Analysis
The moat-strength module scores 88/100, with GLP-1 Franchise Leadership: Co-leader, Manufacturing Scale as Moat: Advantage. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
LLY Free Cash Flow vs Net Income
CF/Net Income: 0.83x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 72/100. For the diagnostic, start with cash flow vs net income.
LLY Key Risks from the Annual Report
The risk module scores 66/100, with GLP-1 Supply Execution: Live risk, Novo Nordisk Competition: Intense. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is LLY a High Quality Earnings Stock?
Based on this 2024 filing, LLY passes the first screen for high-quality earnings: the overall grade is C, and the earnings-quality score is 83/100. This is a research screen, not investment advice.
Read the report first
Understand Eli Lilly and Company first, then decide if it belongs on your watchlist
The LLY score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep LLY with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the LLY report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross margin of 81.3% reflects Lilly's concentration in high-priced patent-protected biologics (Mounjaro, Zepbound, Verzenio, Jardiance) rather than generics or low-margin commodities. Structurally elite for a pharma.
Revenue grew ~32% to $45.0B from $34.1B in FY2023. Mounjaro (type 2 diabetes) and Zepbound (obesity, launched Dec 2023) are the primary drivers. No other mega-cap pharma grew anywhere near this rate in FY2024.
OCF of $8.8B against NI of $10.6B = 0.83x conversion — below the 1.0x quality threshold. Working-capital buildup (accounts receivable expanding with revenue, inventory pre-builds for launches) suppresses OCF during growth phases. Normalizes as revenue settles.
R&D spend runs ~24% of revenue, even higher than JNJ's ~19%. Lilly invested aggressively in GLP-1 successors (retatrutide), Alzheimer's (Kisunla, approved July 2024), oncology (Verzenio). Heavy reinvestment into the next wave is the structural choice.
Earnings quality scores 83/100. 81.3% gross margin + 32% revenue growth is a rare combination at mega-cap scale. The 0.83x CF/NI is the one soft spot — typical for growth-phase pharma where working capital expands with every new launch — not a sign of accrual manipulation. Heavy R&D reinvestment (~24%) funds the post-GLP-1 pipeline; this compounds the earnings-quality story long-term even at the cost of near-term margin.
Moat Strength
Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) are one of two dominant GLP-1 franchises globally (with Novo Nordisk's Ozempic/Wegovy). Tirzepatide's dual GIP/GLP-1 mechanism produces superior weight loss in head-to-head data. Patent exclusivity runs into the early 2030s.
GLP-1 peptide manufacturing requires specialized capacity that takes 3-5 years to build. Lilly's aggressive capex (multiple new plants in Indiana, North Carolina, Germany, Ireland) is a moat in its own right — new entrants can't just appear, they must match the build-out.
Beyond GLP-1, Lilly has Kisunla (Alzheimer's, approved July 2024), Verzenio (breast cancer, growing), Jardiance (diabetes, partnered with Boehringer), Taltz (psoriasis), and next-gen obesity candidate retatrutide in late-stage trials. Pipeline diversification reduces single-franchise risk.
Tirzepatide core patents extend into early 2030s; Kisunla, Verzenio, and pipeline assets have fresh patent windows. Unlike ABBV post-Humira or JNJ post-STELARA, Lilly does not face a near-term patent cliff on its largest franchise.
Moat strength scores 88/100. GLP-1 co-leadership is the defining moat — tirzepatide's dual mechanism + patent runway + manufacturing scale combine into a decade-plus advantage. Kisunla adds Alzheimer's optionality (first-in-class amyloid therapy with durability). Pipeline depth reduces concentration risk. The moat is 'wide' by Dorsey standards but commodity-price-like (reimbursement pressure from payers, ICER cost-effectiveness reviews) erosion is real over 10+ years.
Capital Allocation
FCF of $8.8B on $45B revenue = 19.5% FCF margin — lower than typical pharma (25-30%) because Lilly is in peak capex mode. Multi-plant GLP-1 manufacturing build costs $6B+ over multiple years; near-term FCF is compressed while capacity matures.
ROE of 74.2% (NI $10.6B / Equity $14.3B) — elevated by buybacks leaving a thin equity base. Underlying ROA is a more modest 15% ($10.6B / $72.3B assets). Capital structure is moderately leveraged (81.9% debt ratio) to fund both buybacks and the capex build.
Lilly has raised dividends for 10+ consecutive years with double-digit growth recently. FY2024 dividend payout was ~$5B. Coverage is comfortable at $8.8B FCF, though the FCF-to-dividend ratio tightens until capex cycle peaks.
Capex as % of revenue runs ~20% — exceptional even for a manufacturing-intensive pharma. This reflects the GLP-1 buildout; expect it to normalize to 8-10% once global manufacturing footprint is established by FY2026-27.
Capital allocation scores 72/100. Lilly is in an unusual position — high ROE + high capex + growing dividends all simultaneously. The 20% capex intensity will moderate post-GLP-1 buildout, releasing FCF. The 74% engineered ROE is fine given strong underlying ROA and the obvious investment opportunity. The one caveat: if GLP-1 demand disappoints or Novo Nordisk gains share faster than expected, the capex commitment becomes harder to digest.
Key Risks
The 10-K flags 'issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages.' Zepbound demand exceeded supply throughout FY2024; compounded GLP-1 competition from pharmacies took share during shortages. Flawless capex execution is the counter-narrative.
Novo Nordisk's Ozempic/Wegovy has been the GLP-1 category-defining brand since 2021. Novo's next-gen oral semaglutide + manufacturing partnership with Catalent compete directly with Lilly's pipeline. This is a two-horse race with real daylight between #2 and #3 but intense rivalry at the top.
GLP-1 list prices ($1000+/month) strain health plans; Medicare Part B inflation rebates + IRA drug-price negotiation put Mounjaro/Zepbound on the long-term target list. ICER cost-effectiveness reviews and payer coverage restrictions are rising.
The 10-K explicitly flags: 'the use of artificial intelligence or other emerging technologies in various facets of our operations may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks.' Management is acknowledging that AI-enabled drug discovery and competitive dynamics are real uncertainties.
Risk profile scores 66/100 (higher = safer). Three of the four risks are directly tied to GLP-1 — supply execution, Novo competition, payer pressure on list prices. The fourth (AI) is a broader industry concern Lilly explicitly surfaced in Risk Factors. None are catastrophic in a single-year view, but the concentration of upside (and risk) in a single therapeutic area is notable. Lilly's pipeline diversification beyond GLP-1 is the mitigation.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.